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Abstract
Background: Restless legs syndrome (RLS) is a chronic disorder with substantial impact on quality of life similar to
that seen in diabetes mellitus or osteoarthritis. Little is known about the psychological characteristics of RLS
patients although psychological factors may contribute to unfavourable treatment outcome.
Methods: In an observational cross-sectional design, we evaluated the psychological features of 166 consecutive
RLS patients from three outpatient clinics, by means of the Symptom Checklist 90-R (SCL-90-R) questionnaire.
Additionally, the Beck Depression Inventory-II (BDI-II) and the International RLS Severity Scale (IRLS) were measured.
Both treated and untreated patients were included, all patients sought treatment.
Results: Untreated patients (n = 69) had elevated but normal scores on the SCL-90-R Global Severity Index (GSI; p =
0.002) and on the sub-scales somatisation (p < 0.001), compulsivity (p = 0.003), depression (p = 0.02), and anxiety (p =
0.004) compared with a German representative sample. In the treated group, particularly in those patients who were
dissatisfied with their actual treatment (n = 62), psychological distress was higher than in the untreated group with
elevated scores for the GSI (p = 0.03) and the sub-scales compulsivity (p = 0.006), depression (p = 0.012), anxiety (p =
0.031), hostility (p = 0.013), phobic anxiety (p = 0.024), and paranoid ideation (p = 0.012). Augmentation, the most
serious side effect of dopaminergic, i.e. first-line treatment of RLS, and loss of efficacy were accompanied with the
highest psychological distress, as seen particularly in the normative values of the sub-scales compulsivity and anxiety.
Generally, higher RLS severity was correlated with higher psychological impairment (p < 0.001).
Conclusion: Severely affected RLS patients show psychological impairment in multiple psychological domains
which has to be taken into account in the treatment regimen.
Keywords: restless legs syndrome, psychological impairment, psychopathology, depression, anxiety, compulsivity,
somatisation
Background
Restless legs syndrome (RLS) is a common neurological
disorder in Western countries with a lifetime prevalence
of 7 to 10% [1]. Approximately 1 to 3% of patients require
treatment [2]. The disease specific, health-related, and psy-
chosocial quality of life of this population is reduced com-
pared to the general population and is comparable to that
of patients with type 2 diabetes mellitus and osteoarthritis
[2,3]. The lifetime prevalence of comorbid depression and
anxiety disorders is elevated by odds ratios of 2.1 to 5.3 in
RLS compared to the community at large [4-6]. Sleep
problems, leg dysaesthesias, and the psychological sequelae
of the disorder are all particularly implicated in contribut-
ing to impaired daily functioning [7,8]. RLS is considered
to be a chronic disorder as causative treatments do not
exist except of a few secondary forms such as iron defi-
ciency. Dopamine agonists, the first-line treatment in RLS,
show efficacy which is, however, moderate [9] and the
majority of patients do not experience full remission in
drug trials [10,11]. Little is known about the psychopatho-
logical state and psychological wellbeing of RLS patients.
This issue is, however, of major clinical relevance as psy-
chological factors may contribute to an unfavourable treat-
ment outcome as seen for example in chronic pain
conditions [12]. One study investigated personality traits,
i.e. stable patterns of behaviour, thoughts, and emotions,
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vated neuroticism scores in RLS (n = 42) compared with
non-RLS subjects (n = 982) [13].
I nt h ep r e s e n ts t u d yw ei n v e s t i g a t e dt h ep s y c h o l o g i c a l
impairment of RLS patients in a cross-sectional observa-
tional design. To evaluate the psychological profile, we
used the Symptom-Checklist-90-Revised version (SCL-90-
R [14,15]), a broadly used self-report inventory which cap-
tures the main dimensions of the actual psychopathology
of a person in nine sub-scales and a Global Severity Index
(GSI). Additionally, depressive symptoms were assessed
using the Beck Depression Inventory.
Methods
Data of 166 consecutive German patients was collected
over a period of 12 months (October 2006 until October
2007). These patients sought treatment for RLS at the RLS
outpatient clinic at the University Medical Centre Freiburg
(affiliated to the Sleep Disorders Centre of the Dept. of
Psychiatry and Psychotherapy to that time; n = 111), in
the Sleep Disorders Centre in Schwerin (Somni bene Insti-
tute for Medical Research and Sleep Medicine; n = 15) and
the Sleep Disorders Centre of the Department of Clinical
Neurophysiology in Bremen (n = 40). A detailed descrip-
tion of the patient population, including comorbidity and
medication, is presented in the Results section.
Diagnosis was made according to valid diagnostic cri-
teria (IRLSSG [16]) in a face-to-face interview by clini-
cians with experience in RLS diagnosis (MH, SH, HB)
and was confirmed by the RLS Diagnostic Index [17].
Patients completed the study questionnaires (see below)
and were evaluated according to age, gender, medication,
former and current treatment of RLS, satisfaction with
the actual treatment, and comorbid disorders as noted in
the medical history. Those patients that were not able to
fill in the questionnaires (cognitively disabled or illiter-
ates) were excluded from the study. Also patients with
incompletely filled in questionnaires were not included in
the centres Bremen and Schwerin. In the centre Freiburg,
the questionnaires were inspected regarding missing data
during the clinical investigation and were completed
together with the patient if necessary. For the subgroup
analyses, patients were classified according to their treat-
ment status. The group of untreated patients comprised
a) treatment naïve and b) currently untreated patients
with treatment experience. The group of treated patients
were a) patients who were satisfied with the actual treat-
ment and b) patients who were dissatisfied with the
actual treatment regimen. The group of dissatisfied
patients was then assigned in each centre to three sub-
groups i) augmentation, ii) loss of efficacy, and iii) other
side effects according to the judgement of the local inves-
tigator. At the time of data collection, diagnostic criteria
and severity rating scales for augmentation were not
established; therefore, augmentation severity was not
evaluated in the study. The study was approved by the
local ethics committee and all patients gave written
informed consent.
Questionnaires
The Symptom-Checklist-90-R (SCL-90-R [14,15]) is a
validated 90-item multidimensional self-rating question-
naire originally developed to assess the psychopathology
of psychiatric and medical outpatients and further
extended to measure psychological distress in a wide
range of populations. It assesses a broad range of physical
and psychological symptoms that might have bothered or
distressed the subjects in the past seven days. Each of the
90 items is rated on a 5-point scale (ranging from 0 to 4),
with higher values indicating greater impairment. The
items build nine sub-scales: somatisation, compulsivity,
interpersonal sensitivity, depression, anxiety, hostility,
phobic anxiety, paranoid ideation, and psychoticism. The
Global Severity Index (GSI) is derived from all items and
indicates the degree of overall psychological distress/
impairment. Raw scores for the sub-scales and the GSI
are calculated ranging between 0 - 4 (0 = no distress to
4 = maximal distress). These can be transformed into age
and gender-specific normative values (T-value, normal
range 50 ± 10, higher values indicating greater psycholo-
gical distress) by using the standardisation reference table
[14,15]. The sub-scales show satisfactory reliability in
chronic pain patients who are similarly impaired as RLS
patients. Cronbach’s alpha range from a =0 . 7 1t oa =
0.89, the GSI is very consistent with a Cronbach’sa l p h a
of a = 0.97 [18].
The Beck Depression Inventory-II (BDI-II [19]) is a 21
item self-rating scale for assessing the experience of
depressive symptoms in the preceding seven days. The
item-response scales range from 0 to 3, with higher
scores indicating more severe depressive symptoms. The
sum score can range from 0 to 63 points. A score ≥ 18
points indicates clinically relevant depression. Good to
very good reliability (0.84 ≤ a ≤ 0.92) was reported for
the BDI-II in psychiatric, chronic pain and non-clinical
populations [20-23].
RLS severity was additionally assessed using the vali-
dated International RLS Severity Scale (IRLS; Cronbach’s
a = 0.93-0.95 [24]). The self-rating questionnaire
includes ten items (responses ranging from 0 to 4) eval-
uating the symptom severity and the impact of symp-
toms on everyday life activities. A total score of 1 to 10
points indicates mild, 11 to 20 moderate, 21 to 30
severe, and 31 to 40 very severe RLS symptoms.
Statistical analysis
Demographic characteristics were analysed using analy-
sis of variance, Kruskal-Wallis test, and chi
2 test. The
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tests in order to detect differences between patient
groups. Sub-scales of the SCL-90-R of untreated patients
were also compared with the reference scores of a
German representative sample [25] using one sample
t-tests. Spearman rank correlation was used for correla-
tion analysis. No adjustment for multiplicity of statistical
analyses was performed in this exploratory study.
Results
Patient population
Characteristics of the study population are shown in
Table 1. Patients were 59.6 ± 12.9 years old, 65.7% were
female. The mean IRLS score was 27.2 ± 7.7 and the
BDI-II score was 13.0 ± 9.1. Age (p = 0.23), gender (p =
0.75), psychological symptoms as assessed by the BDI-II
(p = 0.35), and RLS severity as assessed by the IRLS (p =
0.75) were not different in the three study centres.
The actual medication was levodopa in 46% of patients,
dopamine agonists in 22%, a further 10% received combi-
nations of two dopamine agonists, and 12% received
dopaminergic substances that were combined with other
treatments. Four percent of patients received opioids, 2%
anticonvulsants, and 3% other unspecific treatments.
Notably, in the augmentation group, all patients received
dopaminergic treatment: levodopa (n = 8), dopamine
agonists (n = 7), combination of both (n = 3), or a dopa-
mine agonist with opioids (n = 1). Comorbid disorders
were documented in 74% of patients: 63% in untreated
and 81% in treated patients.
Iron deficiency was documented in two patients (one
untreated patient and one patient with augmentation). It is
noteworthy that at the time of data collection we did not
routinely screen patients for iron deficiency. One patient
had renal failure and was satisfied with her RLS treatment.
Psychological characteristics of patients
SCL-90-R data are presented in Table 1. RLS patients
revealed normative SCL-90-R scores in the upper nor-
mal range (T-values < 60; Table 2). Compared to a
German representative population sample [25] we found
in untreated patients elevated raw scores on the sub-
scales somatisation (p < 0.001), compulsivity (p = 0.003),
depression (p = 0.02), anxiety (p = 0.004), and on the
Global Severity Index (GSI; p = 0.002). Normative values
of these sub-scales were in the normal range indicating
no clinically relevant abnormality.
Considering the whole study population, the extent of
psychological problems correlated with RLS severity
(GSI of SCL-90-R and IRLS; r = 0.4; p < 0.001).
Table 1 Psychometric data of the study population
Untreated
patients
(N = 69)
Treated patients
Satisfied with the actual
treatment
(N = 35)
Dissatisfied with the actual treatment
Augmentation (N =
19)
Loss of
efficacy
(N = 35)
Side
effects
(N = 8)
IRLS 24.0 (8.8) 26.9 (5.6) 31.4 (4.1)** 31.6 (5.9)*** 27.1 (5.8)
BDI-II 11.3 (8.9) 12.0 (8.4) 15.8 (8.3)* 16.1 (10.3)* 11.9 (5.4)
SCL-90-R
GSI 0.7 (0.6) 0.7 (0.5) 1.0 (0.6)* 0.9 (0.6) 0.6 (0.3)
Somatisation 0.9 (0.6) 0.9 (0.6) 1.2 (0.6)* 1.2 (1.1) 0.8 (0.4)
Compulsivity 0.8 (0.7) 0.8 (0.8) 1.2 (0.8)* 1.2 (0.9)* 0.9 (0.4)
Insecurity in social
contact
0.8 (2.7) 0.6 (0.6) 0.9 (0.6)* 06. (0.6) 0.5 (0.5)
Depression 0.7 (0.8) 0.8 (0.8) 1.0 (0.8) 1.0 (0.8)* 0.8 (0.4)
Anxiety 0.6 (0.1) 0.7 (0.5) 0.9 (0.6)* 0.8 (0.6) 0.4 (0.3)
Hostility 0.4 (0.5) 0.5 (0.5) 0.8 (0.6)** 0.6 (0.7) 0.4 (0.3)
Phobic anxiety 0.4 (0.6) 0.2 (0.4) 0.5 (0.7) 0.5 (0.6)* 0.2 (0.2)
Paranoid ideation 0.4 (0.5) 0.4 (0.5) 0.8 (0.7)** 0.6 (0.6) 0.3 (0.2)
Psychoticism 0.4 (0.7) 0.3 (0.7) 0.6 (1.0) 0.4 (0.5) 0.2 (0.2)
*: p < 0.05; **: p < 0.01; ***: p < 0.001
Raw scores of sub-scales and Global Severity Index (GSI) of the SCL-90-R are presented. Values are mean (SD). Statistically significant results refer to comparisons
of each group with untreated patients.
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A flow diagram of the study population is provided in
Figure 1. Untreated patients were slightly younger than
treated patients without treatment problems and treated
patients with treatment problems (56.1 ± 12.9, 61.9 ±
9.6, 62.2 ± 13.6, respectively; p = 0.03), the gender dis-
tribution was comparable in the subgroups (p = 0.1).
SCL-90-R scores of treatment-naïve and at the time
untreated patients but with treatment experience were
comparable (0.16 ≤ p ≤ 0.83). The groups of treatment-
naïve and at the time untreated patients were merged for
the statistical analysis and are further reported as the
group of untreated patients. Compared with these
untreated patients, the treated group showed higher
scores on the SCL-90-R sub-scales compulsivity (1.0 ±
0.8 vs. 0.8 ± 0.7, p = 0.044; raw data values), depression
(0.9 ± 0.8 vs. 0.7 ± 0.9, p = 0.028), anxiety (0.8 ± 0.5 vs.
0.6 ± 0.6, p = 0.048), and hostility (0.6 ± 0.6 vs. 0.4 ± 0.5,
p = 0.032) as well as on the IRLS (29.5 ± 5.9 vs. 24.0 ±
8.8, p < 0.001) and the BDI-II (14.2 ± 9.0 vs. 11.3 ± 8.9,
p = 0.010). When analyzing the subgroups of treated
patients, those dissatisfied with their treatment accounted
for the higher IRLS scores (Table 1) and revealed the
highest psychological distress. Compared with untreated
patients, the SCL-90-R sub-scales compulsivity, depres-
sion, anxiety, hostility, phobic anxiety, paranoid ideation,
and the GSI were elevated in these patients (Figure 2).
The highest scores were seen in the sub-scales somatisa-
tion, compulsivity, depression, and anxiety. In this sub-
group, augmented patients were those most affected by
psychological symptoms compared with untreated
patients (Table 1). Normative SCL-90-R scores of
patients with augmentation and those with loss of effi-
cacy were markedly elevated in the sub-scales compulsiv-
ity and anxiety (T-values > 60; Table 2), these patients
Table 2 Normative values of the SCL-90-R sub-scales and GSI in the study population
Untreated
patients
(N = 69)
Treated patients
Satisfied with the actual
treatment
(N = 35)
Dissatisfied with the actual treatment
Augmentation
(N = 19)
Loss of
efficacy
(N = 35)
Side
effects
(N = 8)
SCL-90-R
GSI 56.1 (10.2) 56.4 (11.0) 62.2 (10.3) 61.0 (11.6) 56.6 (4.0)
Somatisation 56.0 (9.9) 56.2 (9.5) 61.8 (10.5) 58.3 (12.6) 56.2 (4.6)
Compulsivity 56.1 (11.5) 56.0 (11.0) 62.0 (11.7) 62.4 (12.2) 59.6 (4.9)
Insecurity in social
contact
53.0 (10.1) 55.0 (10.6) 59.9 (10.6) 56.4 (11.7) 53.3 (10.4)
Depression 54.1 (10.0) 56.5 (12.4) 59.4 (12.7) 60.2 (12.5) 58.4 (5.7)
Anxiety 56.0 (10.6) 57.0 (10.0) 62.4 (8.3) 60.4 (9.5) 54.4 (5.7)
Hostility 53.0 (9.7) 55.5 (9.3) 61.0 (8.8) 57.8 (11.7) 52.9 (8.6)
Phobic anxiety 51.8 (10.6) 48.5 (9.4) 56.6 (11.4) 56.1 (10.9) 50.1 (7.7)
Paranoid ideation 50.0 (9.4) 49.9 (9.3) 58.1 (9.5) 53.4 (10.6) 50.0 (6.2)
Psychoticism 53.7 (9.2) 52.3 (9.7) 57.8 (12.7) 55.9 (10.4) 53.4 (6.3)
Values are mean (SD). Bold letters indicate values above the normal range (T-values > 60), higher values indicate higher distress.
Study population
N = 166
Untreated 
patients 
N = 69
Treated 
patients 
N = 97
Augmentation 
N = 19
Loss of 
efficacy 
N = 35
Side 
effects 
N = 8
Without treatment 
problems
N = 35
With treatment 
problems 
N = 62
Figure 1 Flow diagram of study population.
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toms (IRLS: 31.4 ± 4.1 and 31.6 ± 5.9, Table 1).
Clinically relevant depression (BDI-II score ≥ 18) was
present in 23% of the whole patient population. The lar-
gest proportion of patients with clinically relevant
depressive symptoms was dissatisfied with treatment
(29%). Depressive symptoms were most elevated in
patients with augmentation or loss of efficacy (Table 1).
Discussion
We investigated psychological distress in patients with
RLS in a cross-sectional study. This study has two major
findings: Firstly, RLS patients who are untreated show
slightly elevated psychological distress in the domains
somatisation, compulsivity, depression, and anxiety com-
pared to representative values. Second, the psychological
distress increases with the experience of frustrane treat-
ments such as loss of efficacy and augmentation and can
lead to clinically relevant psychological problems particu-
larly in the domains of compulsivity and anxiety. The
study yielded new evidence on psychological impairment
of patients with RLS as to our knowledge no other study
investigated the whole spectrum pf psychopathology in
RLS. Of particular interest is our finding of elevated
somatisation, which is frequently found in chronic disor-
ders [18,26-30]. Corresponding to this finding, a recent
study described a high rate of somatoform disorders
(41%) and of chronic pain (34%) in RLS patients [31], and
these comorbidities contributed to an unfavourable RLS
treatment outcome [31]. A further interesting finding is
the relatively high score for compulsive behaviour, parti-
cularly in treated patients. This finding is in line with
recent observations reported in connection with the
occurrence of impulse control disorders, such as patholo-
gical gambling, shopping addiction, and drug hoarding
during dopaminergic treatment in Parkinson’sd i s e a s e
[32] and RLS [33,34]. Reported drug hoarding and
increased medication consumption that was associated
with augmentation [34] corresponds to our observation
of elevated compulsivity in augmented patients. Elevated
depression and anxiety scores have been reported in RLS
(for review see [35]), our findings are in line with these
studies.
The psychological burden appears to be the highest in
patients with augmentation followed closely by those
experiencing loss of treatment efficacy. An explanation
for this, though not specific to RLS, may be that frustra-
tion encountered during the course of treatment may
promote feelings of helplessness and negative cognitions
such as catastrophic thoughts.
The main limitation of the study is its cross-sectional
design. Therefore, it remains difficult to judge whether
0
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Figure 2 SCL-90-R sub-scales and Global Severity Index in RLS patients. Presented are the three patient groups (shaded bars): untreated
patients, patients satisfied with the treatment and patients dissatisfied with their actual treatment. Patient groups with significantly higher scores
compared with those of the group untreated patients are indicated with asterisks. SCL-90-R scores of a representative German population
sample [25] are presented also (horizontal line). GSI: Global Severity Index. *: p < 0.05, **: p < 0.01.
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posed by psychological factors to the development of
psychological problems or whether the treatment itself,
including dopaminergic therapy, may impact psychologi-
cal functioning. Longitudinal studies observing the
change in burden experienced over time in routine care
are needed. In future studies the influence of comorbid
chronic disorders and intake of non-RLS specific medi-
cations should be considered. A more detailed assess-
ment of treatment problems is also required. A selection
bias may exist in the centres Bremen and Schwerin,
where patients with incomplete questionnaires were not
included in the study. Comparison of the populations in
the centres revealed, however, no differences in the
main characteristics such as age, gender, psychological
symptoms, or RLS severity.
Severely affected RLS patients show psychological
impairment with abnormalities in multiple psychological
domains. These particularly interesting abnormalities
should be considered in the treatment of RLS patients.
For some severely affected patients, psychological sup-
port may be necessary. Patients can benefit from being
educated in coping strategies that enable the patients to
deal better with the disorder and prevent exacerbation of
psychological symptoms [36,37]. Cognitive interventions
may help in better coping with depressive and anxiety
symptoms and mindfulness-based exercises [36,37] may
reduce the sympathetic hyperactivity described in RLS
[38]. In a pilot study, such strategies were applied suc-
cessfully to a group of patients with mild to moderate
RLS [36,37].
Conclusions
In conclusion, patients with RLS show elevated psycholo-
gical distress in multiple psychological domains. More
severe RLS symptoms are associated with elevated psy-
chological impairment. The psychological distress may
contribute to an unfavourable treatment outcome and
has to be taken into account in the treatment regimen of
severely affected patients.
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